UVC Disinfection: The New Standard of Care?
The first UVC disinfection was introduced to the market in 2007. Since that time, prestigious hospitals and health care systems across the U.S. have invested in the technology, including Duke University, the University of Wisconsin, Vanderbilt University, many VA hospitals and more. The Centers for Disease Control and Prevention also funded the first and only randomized clinical trial on UVC disinfection, which was conducted across nine hospitals in the Duke Infection Control Outreach Network between 2012 and 2014.
In the landmark study, a measured dose of UVC was shown to reduce bioburden and epidemiologically-important pathogens by 94%, which has been shown to result in a 35% reduction in colonization and infections in hospital settings with 93% compliance of standard disinfection protocols.*
While adoption of enhanced, “no-touch” disinfection technology has increased significantly, the COVID-19 pandemic has also changed how hospitals are using these devices. Historically, UVC devices have been used in patient rooms after an isolation patient has been discharged as well as nightly in the operating room(s). More recently, these devices are often being used daily in all patient rooms, public areas, sterile processing and other spaces within the facility.
The COVID-19 pandemic has also brought to light the importance of surfaces receiving a measured dose of UVC energy, in order to ensure all areas of a room are adequately disinfected. Devices that rely on a fixed cycle time and/or multiple positions around the room provide inefficient disinfection and missed areas. A precise, measured dose of UVC energy minimizes that risk by calculating the time needed to react to room variables – such as size, geometry, surface reflectivity and the amount and location of equipment in the room.
Click here to read more about Tru-D’s technology.